Testing effectiveness (Phase 2)WithdrawnNCT03220009
What this trial is testing
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
Who this might be right for
Cervical CarcinomaEsophageal CarcinomaMucosal Melanoma+14 more
National Cancer Institute (NCI)